How can human biology data improve target selection? Learn how one discovery programme identified a potential new treatment for opioid use disorder.
Choosing the right therapeutic target is one of the biggest challenges in early drug discovery, particularly for diseases driven by multiple biological pathways. Rather than focusing on a single protein, researchers are using AI to analyse human-derived biological data and identify mechanisms that may offer stronger therapeutic potential before compounds enter preclinical testing.
Opioid use disorder (OUD) is one such example. The condition involves widespread changes across neuronal signalling, neuroplasticity and reward pathways, making it difficult to address through modulation of a single molecular target. Researchers are now investigating whether AI can help identify combinations of targets that better reflect the biology of the disease.
Jayson Uffens, Chief Technology Officer, Co-founder and Chairman of GATC Health, believes AI should be used to support biological reasoning rather than simply identify statistical patterns within large datasets.
“My role sits at the intersection of AI systems design, biological modelling and real-world therapeutic development,” Uffens explained. “A lot of what I do is building that bridge between an AI platform, our scientists and the wet lab.”
Drug Target Review spoke with Uffens about how AI is being applied to target identification, why human-derived multiomic data matters and how GATC Health’s Operon platform was used to design a potential treatment for OUD.
Already a member? Sign in